Teva’s Version of Neupogen Approved by FDA

The US FDA (Food and Drug Administration) have approved Teva Pharmaceutical Industries’ form of Amgen’s severe neutropenia therapy, Neupogen. The FDA have approved tbo-filgrastim, which Teva noted is the first new granulocyte colony-stimulating factor (G-CSF) to be backed by the US agency in over 10 years.  The drug is a copy of Neupogen (filgrastim), which

Continue Reading

Generic Actos Launched by Mylan, Teva and Ranbaxy

Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is

Continue Reading

Teva Won’t Launch Generic Lipitor in US

Teva Pharmaceuticals have decided not to retail atorvastatin, a generic version of Pfizer’s blockbuster cholesterol medication Lipitor, in the US. In December 2011, the Israeli drug maker signed an agreement with Ranbaxy Laboratories to help Ranbaxy during the 180-day exclusivity period they had to sell their copycat version of Lipitor (atorvastatin).  The agreement has resulted

Continue Reading

Teva Sales Rise By 28%, Boosted By Cephalon Acquisition

Teva Pharmaceutical Industries announced a solid set of financials for their fourth quarter today. The financials were enhanced by sales of Teva’s multiple sclerosis drug, Copaxone, and from the contribution of recently-acquired Cephalon, which helped shift Teva further away from its original identity as a generic-drug maker. Teva’s net income increased by 23% to $1.40

Continue Reading

FDA Approves Teva’s Generic Version of Lipitor

Generics major Teva Pharmaceutical Industries is set to enter the lucrative market created in the USA by the patent expiry on Pfizer’s Lipitor but not until Ranbaxy Laboratories’ 180-day exclusivity period runs out. The Israeli drugmaker noted that the US FDA (Food and Drug Administration) have granted tentative approval for their generic version of Lipitor,

Continue Reading

Teva and Alcobra Report Positive Data for ADHD Drug

Teva and partner Alcobra have reported new positive data on a candidate drug for attention-deficit hyperactivity disorder (ADHD) and have announced that they are planning to advance it to a full Phase III trials programme next year. The success of the Phase II trial of MG01CI, an extended release formulation of Metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate), has

Continue Reading